Abstract
Chemotherapy-induced peripheral neurotoxicity (CIPN) is a major clinical problem since it is the dose-limiting side effect of a significant number of antineoplastic drugs. The incidence of CIPN varies depending on the conditions, but severe neuropathy can occur in up to 40% of patients undergoing a polichemotherapy regimen. Moreover, even when CIPN is not a dose-limiting side effect, its onset may severely affect the quality of life of cancer patients and cause chronic discomfort. Currently, no treatment is available which can significantly improve the clinical signs and symptoms of CIPN. In recent years, new agents have been proposed as neuroprotectants, and some of them have been more specifically studied for CIPN. So far, the most interesting results for future applications have been obtained in the pre-clinical studies involving cytokines and growth factors. For several of these drugs, in fact, sound hypotheses have been formulated to support the idea of a protective role on selected neuronal targets. However, this theoretical basis has frequently failed to lead to consistent results in pre-clinical and clinical applications. We will review the state-of-the-art of CIPN treatment with growth factors and focus on the future prospects opened up by the most recent pre-clinical and clinical studies.
Keywords: Chemotherapy, peripheral neuropathy, neurotoxicity, neuroprotection, growth factors
Current Drug Safety
Title: The Role of Growth Factors in the Prevention and Treatment of Chemotherapy-Induced Peripheral Neurotoxicity
Volume: 1 Issue: 1
Author(s): Guido Cavaletti and Paola Marmiroli
Affiliation:
Keywords: Chemotherapy, peripheral neuropathy, neurotoxicity, neuroprotection, growth factors
Abstract: Chemotherapy-induced peripheral neurotoxicity (CIPN) is a major clinical problem since it is the dose-limiting side effect of a significant number of antineoplastic drugs. The incidence of CIPN varies depending on the conditions, but severe neuropathy can occur in up to 40% of patients undergoing a polichemotherapy regimen. Moreover, even when CIPN is not a dose-limiting side effect, its onset may severely affect the quality of life of cancer patients and cause chronic discomfort. Currently, no treatment is available which can significantly improve the clinical signs and symptoms of CIPN. In recent years, new agents have been proposed as neuroprotectants, and some of them have been more specifically studied for CIPN. So far, the most interesting results for future applications have been obtained in the pre-clinical studies involving cytokines and growth factors. For several of these drugs, in fact, sound hypotheses have been formulated to support the idea of a protective role on selected neuronal targets. However, this theoretical basis has frequently failed to lead to consistent results in pre-clinical and clinical applications. We will review the state-of-the-art of CIPN treatment with growth factors and focus on the future prospects opened up by the most recent pre-clinical and clinical studies.
Export Options
About this article
Cite this article as:
Cavaletti Guido and Marmiroli Paola, The Role of Growth Factors in the Prevention and Treatment of Chemotherapy-Induced Peripheral Neurotoxicity, Current Drug Safety 2006; 1 (1) . https://dx.doi.org/10.2174/157488606775252656
DOI https://dx.doi.org/10.2174/157488606775252656 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Purine Derivatives as Ligands for A3 Adenosine Receptors
Current Topics in Medicinal Chemistry Role of Hydrogen Sulfide in Systemic and Pulmonary Hypertension: Cellular Mechanisms and Therapeutic Implications
Cardiovascular & Hematological Agents in Medicinal Chemistry Device-based Therapies for Resistant Hypertension
Current Pharmaceutical Design Treatment of Takotsubo Cardiomyopathy
Current Pharmaceutical Design Optimising the Use of Non-Invasive Ventilation in the Intensive Care Setting
Current Respiratory Medicine Reviews Pharmacological manipulation of peripheral vascular resistance in special clinical situations after pediatric cardiac surgery
Current Vascular Pharmacology Transcranial Doppler Ultrasonography: Current Status
Current Medical Imaging Dexmedetomidine: A Novel Anesthetic Agent for Middle Ear Surgery
Recent Patents on CNS Drug Discovery (Discontinued) Toll-like Receptor 4 Mediates LPS-Induced Release of Nitric Oxide and Tumor Necrosis Factor-α by Embryonal Cardiomyocytes: Biological Significance and Clinical Implications in Human Pathology
Current Pharmaceutical Design Nutrient and Qualitative Phytochemical Analysis-evaluation of Antimicrobial Activity and Development of Products with Mulberry Leaves (<i>Mulberry indica</i> L.)
Current Nutrition & Food Science Effects of Physical Exercise on Depressive Symptoms and Biomarkers in Depression
CNS & Neurological Disorders - Drug Targets Cardiovascular Effects of Coumarins Besides their Antioxidant Activity
Current Topics in Medicinal Chemistry Neuroprotective Role of Hypothermia in Hypoxic-ischemic Brain Injury: Combined Therapies using Estrogen
Current Neuropharmacology Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity
Current Medicinal Chemistry A Multicenter, Double-Blind, Placebo-Controlled Trial of the PDE9A Inhibitor, PF-04447943, in Alzheimer's Disease
Current Alzheimer Research Cardiovascular Effects of EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibodies
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacogenetics of Antihypertensive Therapies: Can this be Applied in the Clinic?
Current Pharmacogenomics and Personalized Medicine Clinical and Forensic Aspects of Pharmacobezoars
Current Drug Research Reviews Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy
Current Vascular Pharmacology